IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023 08:00 ET
|
IN8bio, Inc
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced...
IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents
September 19, 2023 08:03 ET
|
IN8bio, Inc
Newly granted patents expand the use of the DeltEx Drug Resistant Immunotherapy (DRI) platform to encompass Chimeric Antigen Receptor T-cell (CAR-T) and checkpoint inhibitors (CPIs).Broadens IN8bio’s...
IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 08:00 ET
|
IN8bio, Inc
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced...
IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
August 15, 2023 08:00 ET
|
IN8bio, Inc
NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced...
IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023 16:15 ET
|
IN8bio, Inc
Presented positive INB-200 Phase 1 data in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting showing 100% of treated patients (n=8) have exceeded historical...
IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility
August 08, 2023 08:00 ET
|
IN8bio, Inc
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline of innovative gamma-delta T cell therapiesThe new site supports...
IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting
June 05, 2023 08:00 ET
|
IN8bio, Inc
100% of treated patients (n=8) to date have exceeded historical median progression-free survival, with two patients that received three doses remaining progression-free at 23.5 and 19.4 months,...
IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
May 17, 2023 08:00 ET
|
IN8bio, Inc
Preclinical results showcase the potential for the strong synergistic combination of chemotherapy and gamma-delta T cell therapy to target solid tumors beyond the brain The DeltEx platform is the...
IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 12, 2023 08:00 ET
|
IN8bio, Inc
Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels in 100% of evaluable treated leukemia patients; Dose Level 2 selected as the...
IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting
May 02, 2023 17:08 ET
|
IN8bio, Inc
Preclinical data demonstrates that gamma-delta T cells have the ability to target other solid tumors such as ovarian cancer, supporting the development of these technologies outside of brain tumorsThe...